Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer.

Huicheng LiuLili BaiLiu HuangNa NingLin LiYijia LiXuejiao DongQiuyang DuMinghui XiaYufei ChenLikun ZhaoYanhu LiQingwu MengJing WangYaqi DuanJie MingAndy Qingan YuanXiang-Ping Yang

Published in: Journal for immunotherapy of cancer (2022)

This study showed the antitumor potential of an anti-TROP2xCD3 bispecific antibody F7AK3 to TNBC tumor cells both in vitro and in vivo. These data demonstrate that F7AK3 has the potential to treat TNBC patients, which warrants further preclinical and clinical evaluation of the F7AK3 in advanced or metastatic TNBC patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
small cell lung cancer
squamous cell carcinoma
prognostic factors
stem cells
signaling pathway
mesenchymal stem cells
machine learning
artificial intelligence
cell therapy